Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dienogest versus continuous combined oral contraceptive on pelvic pain in endometriosis
IRCT20241010063323N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dienogest in endometriosis (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Pelvic pain reduction. Started May 2025; status: completed.
02
Drugs
dienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on IRCT20241010063323N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241010063323N1.